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Dbe beneficial to develop nationwide, uniform rapid-
assessment criteria for potential TEVAR intervention
when rDTAA is suspected.
Although TEVAR should still be considered a highly ad-
vanced procedure that is best performed in a quaternary
center, it should be acknowledged that we are on the verge
of a paradigm shift. The steady increase in the adoption of
TEVAR for rDTAA over a short span of 3 years, the better
disposition rates of patients who have undergone this proce-
dure, and the use of TEVAR for rDTAA even in smaller hos-
pitals are noteworthy. The adoption of TEVAR for rDTAA
is likely to follow similar trends observed in the adoption of
endovascular approaches for treating ruptured abdominal
aneurysms.
Stephen N. Palmer, PhD, ELS, contributed to editing the
manuscript.
References
1. Makaroun MS, Dillavou ED, Kee ST, Sicard G, Chaikof E, Bavaria J, et al.
Endovascular treatment of thoracic aortic aneurysms: results of the phase II
multicenter trial of the GORE TAG thoracic endoprosthesis. J Vasc Surg.
2005;41:1-9.
2. Gopaldas RR, Huh J, Dao TK, LeMaire SA, Chu D, Bakaeen FG, et al. Superior
nationwide outcomes of endovascular versus open repair for isolated descending
thoracic aortic aneurysm in 11,669 patients. J Thorac Cardiovasc Surg. 2010;
140:1001-10.
3. MakarounMS, Dillavou ED,Wheatley GH, Cambria RP. Five-year results of en-
dovascular treatment with the Gore TAG device compared with open repair of
thoracic aortic aneurysms. J Vasc Surg. 2008;47:912-8.
4. Bhamidipati CM, Lapar DJ, Mehta GS, Kern JA, Kron IL, Upchurch GR Jr, et al.
Have thoracic endografting outcomes improved since US Food and Drug Admin-
istration approval? Ann Thorac Surg. 2011;91:1314-22.
5. Cooper DG,Walsh SR, Sadat U, Hayes PD, Boyle JR. Treating the thoracic aorta
in Marfan syndrome: surgery or TEVAR? J Endovasc Ther. 2009;16:60-70.
6. Steuer J, Eriksson MO, Nyman R, Bjorck M, Wanhainen A. Early and long-term
outcome after thoracic endovascular aortic repair (TEVAR) for acute compli-
cated type B aortic dissection. Eur J Vasc Endovasc Surg. 2011;41:318-23.
7. Tang DG, Dake MD. TEVAR for acute uncomplicated aortic dissection: imme-
diate repair versus medical therapy. Semin Vasc Surg. 2009;22:145-51.
8. Chemelli-Steingruber IE, Chemelli A, Strasak A, Hugl B, Hiemetzberger R,
Czermak BV. Evaluation of volumetric measurements in patients with acute
type B aortic dissection—thoracic endovascular aortic repair (TEVAR) vs con-
servative. J Vasc Surg. 2009;49:20-8.
9. Hughes GC, Lee SM, Daneshmand MA, Bhattacharya SD, Williams JB,
Tucker SW Jr, et al. Endovascular repair of descending thoracic aneurysms: re-
sults with ‘‘on-label’’ application in the post Food and Drug Administration ap-
proval era. Ann Thorac Surg. 2010;90:83-9.
10. Patel HJ, Williams DM, Upchurch GR Jr, Dasika NL, Deeb GM. A comparative
analysis of open and endovascular repair for the ruptured descending thoracic
aorta. J Vasc Surg. 2009;50:1265-70.
11. Starnes BW, Quiroga E, Hutter C, Tran NT, Hatsukami T, Meissner M, et al.
Management of ruptured abdominal aortic aneurysm in the endovascular era.
J Vasc Surg. 2010;51:9-18.
12. Jonker FH, Verhagen HJ, Lin PH, Heijmen RH, Trimarchi S, Lee WA, et al. Out-
comes of endovascular repair of ruptured descending thoracic aortic aneurysms.
Circulation. 2010;121:2718-23.
13. Coselli JS, Gopaldas RR. Ruptured thoracic aneurysms: to stent or not to stent?
Circulation. 2010;121:2705-7.
14. Coady MA, Ikonomidis JS, Cheung AT, Matsumoto AH, Dake MD, Chaikof EL,
et al. Surgical management of descending thoracic aortic disease: open and en-
dovascular approaches. A scientific statement from the American Heart Associ-
ation. Circulation. 2010;121:2780-804.
15. Coselli JS, LeMaire SA, Conklin LD, Adams GJ. Left heart bypass during de-
scending thoracic aortic aneurysm repair does not reduce the incidence of para-
plegia. Ann Thorac Surg. 2004;77:1298-303.1016 The Journal of Thoracic and Cardiovascular Sur16. Healthcare Cost Utilization Project, Nationwide Inpatient Sample (NIS). Rock-
ville, MD: Agency for Healthcare Research and Quality; 2001.
17. Healthcare Cost and Utilization Project website: Nationwide Inpatient Sample sec-
tion. Available at: http://www.hcup-us.ahrq.gov/db/nation/nis/nisrelatedreports.jsp.
Accessed January 5, 2011.
18. International Classification of Diseases, Ninth Revision, Clinical Modification.
5th ed. Washington, DC: US Department of Health and Human Services, Public
Health Service; 1988.
19. Orandi BJ, Dimick JB, Deeb GM, Patel HJ, Upchurch GR Jr. A population-based
analysis of endovascular versus open thoracic aortic aneurysm repair. J Vasc
Surg. 2009;49:1112-6.
20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use
with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-9.
21. Deyo RA, Taylor VM, Diehr P, Conrad D, Cherkin DC, Ciol M, et al. Analysis of
automated administrative and survey databases to study patterns and outcomes of
care. Spine. 1994;19:2083S-91S.
22. Gopaldas RR, Bakaeen FG, Dao TK, Walsh GL, Swisher SG, Chu D. Video-as-
sisted thoracoscopic versus open thoracotomy lobectomy in a cohort of 13,619
patients. Ann Thorac Surg. 2010;89:1563-70.
23. Gopaldas RR, Chu D, Dao TK, Huh J, LeMaire SA, Coselli JS, et al. Predictors of
surgical mortality and discharge status after coronary artery bypass grafting in
patients 80 years and older. Am J Surg. 2009;198:633-8.
24. Gopaldas RR, Chu D, Dao TK, Huh J, LeMaire SA, Coselli JS, et al. Impact of
ACGMEwork-hour restrictions on the outcomes of coronary artery bypass graft-
ing in a cohort of 600,000 patients. J Surg Res. 2010;163:201-9.
25. Gopaldas RR, Chu D, Dao TK, Huh J, LeMaire SA, Lin P, et al. Staged versus
synchronous carotid endarterectomy and coronary artery bypass grafting: analy-
sis of 10-year nationwide outcomes. Ann Thorac Surg. 2011;91:1323-9.Discussion
Dr Thomas Gleason (Pittsburgh, Pa). I have no disclosures.
Dr Gopaldas, this was an excellent presentation and a well-written
article. I have a few questions.
First, your primary inclusion code was for ruptured thoracic an-
eurysm, which includes, of course, ascending, arch, and descend-
ing aortic aneurysms, each of which could significantly affect
treatment strategy. How did you ensure that only treatment of
descending thoracic aneurysms was included in your analysis? If
inclusion was based on trapping those in whom there was also
use of cardiopulmonary bypass, this would also not guarantee
exclusion of ascending or arch aneurysms.
Dr Gopaldas. The NIS database captures procedure codes, and
we did use the code that identifies cardiopulmonary bypass with
the use of an oxygenator. This is different from left heart bypass.
So we did exclude all patients who underwent cardiopulmonary
bypass. That ensured all patients with ascending and arch aneu-
rysms were excluded. The one downside to that, however, is
a subset of patients who underwent isolated descending repair
under circulatory arrest were probably excluded.
Now, if there was a way to include that particular subset, it
would have made our analysis stronger, but these are probably
a sicker subgroup of patients, and if they were included in the
model, it probably would have made TEVAR look even better.
Dr Gleason. How about cost? Were you able to establish any
estimates based on the NIS data used as to differences in hospital
cost per patient per group?
Dr Gopaldas.We actually did a cost analysis. I did not include
the slide. There was no statistically significant difference in cost
between TEVAR and open procedures, and even with the risk-ad-
justed model we did not find a difference. The approximate cost
was $20,000 for TEVAR and $19,000 for open repair, a $1000 dif-
ference. But, again, this was not statistically significant.gery c November 2011
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DDr Gleason. In the article, I note that respiratory complications
were actually significantly higher in the TEVAR group compared
with the open group, but despite this fact, length of stay and overall
mortality were lower in that group. Do you have any insight into
this apparent discrepancy?
DrGopoldas.That is a good question, and I was surprised when
we looked through the data. When we ran the analysis for the first
time, wewere surprised partly because our earlier results and stud-
ies on elective cases were exactly the opposite, where the respira-
tory complications were much lower. But the thing to look into and
pay attention to was that respiratory complications also include
pleural effusions or hemothorax and interventions for that. In an
elective case you probably don’t have to deal with much of those,
but when these patients come in with a rupture or potential rupture,
a lot of them have a pleural effusion. When they undergo an open
repair, they automatically have chest tubes placed, and so pleural
effusion is not documented separately. But then when they undergo
TEVAR and still have a persistent pleural effusion, it was docu-
mented for Diagnosis-Related Group billing purposes. They prob-
ably had a thoracentesis and chest tube, and as a result of that, the
percentage of respiratory complications was higher. When we
eliminated pleural effusion, the respiratory complications actually
were lower in the TEVAR subgroup.
Dr Gleason.We are not provided with the relative difference in
the number of open and TEVAR in the smaller and larger hospitals
in the article or presentation. I am curious whether there was a dif-
ference in the percentage of approach by size of hospital. Finally, if
this crude but large data set and analysis can be validated, what
conclusion should be drawnwith respect to the large centers in par-
ticular? It seems this may represent justification for more rather
than less use of open techniques in experienced centers if the mor-
tality and complication rates are shown to be equivalent, as you
have. Given that Dr Coselli’s group has one of the largest practices
in theworld for this disease set, how do you look at this data set and
respond at your own institution? How should this new information
change a large center’s practice?
Dr Gopaldas. Those are valid questions, and the point is well
taken. In cases performed at larger hospitals, 40% of them were
TEVAR, and in smaller hospitals it was approximately 25%, and
there was a statistically significant difference between them.
Now, to answer your question about how large centers should
look at this: I think the focus here was that the significant differ-
ence we noticed was in smaller centers where they had a tactical
advantage in performing TEVAR compared with open repair. Al-
though we did not show a difference in the outcomes in large hos-
pitals between TEVAR and open repair, the one thing we have to
look at is the disposition of these patients. There was a 3 times
greater chance that these patients actually went home after a TE-
VAR when they were in a large hospital. Although there is no dif-
ference in mortality, if you are looking at an elderly subgroup of
patients who are discharged and end up in a nursing home after
an open repair, you are dealing with a lot of problems down the
road, such as bedsores, pulmonary problems, and probably beingThe Journal of Thoracic and Cardebilitated and not going home. So I think TEVAR still has an ad-
vantage in that particular respect.
I did my cardiothoracic residency at Baylor, spent 3 years with
Dr Coselli, and was honored for having spent time there. The way
things are handled there is streamlined. There is a protocol in place
in the emergency department. So if anybody comes to the emer-
gency department and a question of an aortic issue is raised,
they are streamlined for a computed tomography angiogram rather
immediately. If the anatomy is feasible, we always prefer to use
TEVAR as our first option in these circumstances, because it is
quicker to do a femoral artery cutdown and tackle this as long as
the anatomy is feasible and allows that.
Now, I have been at theUniversity ofMissouri for less than1 year,
and we don’t have a hybrid suite; we are building one now. I have
been involved in approximately 12 cases, 2 of them were ruptured
TEVARs and the others were aortic transections. The one thing I
can tell frommy limited experience is that it is a lot easier in themid-
dle of the night towork with an endovascular team, because they are
in the hospital almost every day dealing with a cardiac catheter lab-
oratory emergency or peripheral vascular emergency. On the other
hand, if I have to mobilize the open heart team to come in, it takes
at least 1 to 1.5 hours. I would rather use that time to try an endovas-
cular approach while I get the open heart team in.
So with the availability of the technology and these data, TE-
VAR should be the ideal approach as long as you have a suitable
anatomy and the proper imaging studies.
Dr Gorav Ailawadi (Charlottesville, Va). Using the NIS to
compare 2 different techniques is not ideal because we really
don’t have any information about the anatomy. There is significant
selection bias. You cannot use NIS to compare 2 different proce-
dures and conclude that one is better than another because of these
significant limitations with the database. But my question relates
to the methodology of your inclusion/exclusion related to the pa-
tients that you called ‘‘hybrid.’’ You can use ICD-9-CM codes to
tell us if they had TEVAR or open. What did you do if they had
both? Did you exclude them because you said they were hybrid,
or what if they had a TEVAR and then underwent an open proce-
dure because of a complication or vice versa during the same hos-
pitalization? How can you distinguish this? There really isn’t
a great way to define which day during the hospitalization a partic-
ular procedure occurred. If you exclude these patients, then you ig-
nore complications that may have occurred with either approach.
Dr Gopaldas.We excluded all patients who had both procedures
done in the same hospital admission. TheNISwill allow you to iden-
tify the time difference between the 2 procedures, because it does
have a procedure day code. The problem, however, is that we can’t
tell if the patient had an open approach first and subsequently had
a problem such as a pseudoaneurysm or an anastomotic leak and
needed to have a TEVAR done, or if they had a TEVAR done first
and then it had to be converted to an open procedure later. Because
we couldn’t differentiate these 2 subcategories, we decided to ex-
clude all patients who had both procedures done in the same hospital
admission.diovascular Surgery c Volume 142, Number 5 1017
